Illés Árpád

1.

Obajed Al-Ali, N., Csige, D., Pinczés, L. I., Farkas, K., Rebenku, I., Domján, A., Panyi, G., Szekanecz, Z., Szűcs, G., Illés, Á., Váróczy, L.: Adipokines as Prognostic Biomarkers in Multiple Myeloma: a Case-Control Study.
Medicina (Kaunas). 61 (11), 1-13, (article identifier: 2065), 2025.

doi DEA

Journal metrics:

Q2 Medicine (miscellaneous) (2024)

2.

Brúgós, B., Csirmaz, A., Major, T., Bereczky, Z., Gindele, R., Balogh, G., Kacska, S., Sipos, P., Illés, Á., Pfliegler, G.: Antiangiogenic Treatment of Patients with Hereditary Hemorrhagic Telangiectasia: experience of a Hungarian Center.
J. Clin. Med. 14 (22), 1-12, (article identifier: 8160), 2025.

doi DEA WoS Scopus

Journal metrics:

Q1 Medicine (miscellaneous) (2024)

3.

Illés, Á.: Aplasticus anaemia.
In: Hematológia : Egyetemi jegyzet. Szerk.: Gergely Lajos, Miltényi Zsófia, Váróczy László, Debreceni Egyetemi Kiadó, Debrecen, 83-87, 2025. ISBN: 9789636152529

DEA

4.

Domingo-Domenech, E., Horwitz, S., Pro, B., Illidge, T., Trumper, L., Iyer, S., Advani, R., Bartlett, N. L., Christensen, J. H., Kim, W. S., Feldman, T., Choi, I., Gritti, G., Belada, D., Shustov, A., Illés, Á., Zinzani, P. L., Hüttmann, A., Trneny, M., Le Gouill, S., Jagadeesh, D., Friedberg, J. W., Little, M., Dong, C., Fanale, M., Fenton, K., Savage, K. J.: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.
Blood Cancer J. 15 (1), 1-5, (article identifier: 129), 2025.

doi DEA WoS

Journal metrics:

D1 Hematology (2024)

D1 Oncology (2024)

5.

Pinczés, L. I., Tóthfalusi, D., Dobó, B., Barna, S., Farkas, B., Garai, I., Illés, Á., Miltényi, Z.: [delta]SUVmax adds prognostic value to early response assessment during the first-line treatment of classical Hodgkin lymphoma: a retrospective cohort study.
Cancer Imaging. 25 (1), 1-8, (article identifier: 80), 2025.

doi DEA WoS Scopus

Journal metrics:

Q1 Medicine (miscellaneous) (2024)

Q2 Oncology (2024)

Q1 Radiological and Ultrasound Technology (2024)

Q1 Radiology, Nuclear Medicine and Imaging (2024)

6.

Jóna, Á., Kiss, E., Simon, Z., Illés, Á.: Evaluation of PET/CT during upfront therapy as a prognosticator in follicular lymphoma patients at the University of Debrecen.
Blood. 146 (Suppl.), 5348, 2025.

doi DEA

7.

Brown, J. R., Seymour, J. F., Jurczak, W., Aw, A., Wach, M., Illés, Á., Tedeschi, A., Owen, C., Skarbnik, A. P., Lysak, D., Eom, K. S., Simkovic, M., Pavlovsky, M. A., Kater, A. P., Eichhorst, B., Miller, K., Munugalavadla, V., Yu, T., Borja, M. d., Ghia, P., AMPLIFY investigators: Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
N. Engl. J. Med. 392 (8), 748-762, 2025.

doi DEA WoS Scopus

Journal metrics:

D1 Medicine (miscellaneous) (2024)

8.

Illés, Á.: Hodgkin lymphoma.
In: Hematológia. Szerk.: Gergely Lajos, Miltényi Zsófia, Váróczy László, Debreceni Egyetemi Kiadó, Debrecen, 150-155, 2025. ISBN: 9789636152529

DEA

9.

Illés, Á., Miltényi, Z.: Hodgkin-lymphoma, aplasticus anaemia.
In: Klinikai immunológia. Szerk.: Szekanecz Zoltán, Nagy György, Szűcs Gabriella, Medicina Könyvkiadó Zrt., Budapest, 783-790, 2025. ISBN: 9789632269467

DEA

10.

Tóthfalusi, D., Gulyás, A., Koncz, A., Zöld, É., Illés, Á., Miltényi, Z.: Hodgkin Lymphoma Associated with Common Variable Immunodeficiency: the Role of Early Diagnosis and Multidisciplinary Management.
Hematol Rep. 17 (6), 1-15, (article identifier: 65), 2025.

doi DEA

Journal metrics:

Q3 Hematology (2024)

11.

Tóthfalusi, D., Dobó, B., Borics, F., Pinczés, L. I., Illés, Á., Miltényi, Z.: Impact of Comorbidities on Prognosis and Treatment Outcomes in Elderly Patients with Hodgkin Lymphoma.
Clinics and Practice. 15 (1), 1-16, (article identifier: 15), 2025.

doi DEA Scopus

Journal metrics:

Q2 Medicine (miscellaneous) (2024)

12.

Virga, I., Kósa, K., Illés, A., Miltényi, Z., Ivánka, T., Berecz, R., Égerházi, A., Illés, Á., Magyari, F.: Longitudinal study of cognitive andmental functions among adult Hodgkin-lymphoma survivors, based on data from a primary treatment center in Hungary.
Front Oncol. 15, 1-14, (article identifier: 1509424), 2025.

doi DEA

Journal metrics:

Q2 Cancer Research (2024)

Q2 Oncology (2024)

13.

Jóna, Á., Kiss, E., Illés, Á.: Prognostication of Follicular Lymphoma: a Review of Prognostic Scores and Factors.
Diagnostics. 15 (5), 1-17, (article identifier: 647), 2025.

doi DEA WoS Scopus

Journal metrics:

Q2 Clinical Biochemistry (2024)

Q2 Internal Medicine (2024)

14.

Kiss, E., Simon, Z., Illés, Á., Jóna, Á.: Prognostic Significance of Interim PET/CT in the First-Line Treatment of Follicular Lymphoma Patients, a Single-Center Experience.
Cancers (Basel). 17 (1), 1-10, (article identifier: 73), 2025.

doi DEA WoS Scopus

Journal metrics:

Q2 Cancer Research (2024)

Q1 Oncology (2024)

15.

László, T., Pinczés, L. I., Bátai, B., Varga, L., Timár, B., Gulyás, A., Tárkányi, I., Plander, M., Nagy, Z., Rajnics, P., Egyed, M., Molnár, Z., Rottek, J., Masszi, A., Tamáska, P., Szász, R., Illés, Á., Alpár, D., Magyari, F., Bödör, C.: Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy.
J. Pathol. [Epub ahead of print], 2025.

doi DEA WoS Scopus

Journal metrics:

D1 Pathology and Forensic Medicine (2024)

16.

Kiss, E., Illés, Á., Jóna, Á.: Response Duration During Treatment of Patients with Follicular Lymphoma.
Biomedicines. 13 (6), 1-10, (article identifier: 1433), 2025.

doi DEA

Journal metrics:

Q1 Biochemistry, Genetics and Molecular Biology (miscellaneous) (2024)

Q1 Medicine (miscellaneous) (2024)

17.

Jóna, Á., Illés, Á.: Sequencing Cellular Therapies in the Management of Follicular Lymphoma.
Cells. 14 (21), 1-15, (article identifier: 1671), 2025.

doi DEA

Journal metrics:

Q1 Biochemistry, Genetics and Molecular Biology (miscellaneous) (2024)

18.

Kenyeres, A., Szabó, I. L., Bádon, E. S., Illés, Á., Jóna, Á.: Severe Iron Deficiency Anemia Caused by Long-lasting Bedbug Infestation.
Fortune J. Health Sci. 8 (3), 778-781, 2025.

doi DEA

19.

Garami, G., Obajed, A. A. O., Virga, I., Gulyás, A., Bedekovics, J., Tornai, I., Illés, Á., Magyari, F.: Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation.
Curr Oncol Rep. 32 (2), 1-10, (article identifier: 63), 2025.

doi DEA

Journal metrics:

Q1 Oncology (2024)

20.

Obajed, A. A. O., Pfliegler, G., Magyari, F., Borics, F., Pinczés, L. I., Illés, Á., Brúgós, B.: A Case Report of Hyperhemolytic Syndrome in Sickle Cell Disease, with a Special Focus on Avoiding the Use of Transfusions.
Thalass. Rep. 14 (1), 18-25, 2024.

doi DEA WoS

21.

Kenyeres, A., Kiss, E., Simon, Z., Illés, Á., Jóna, Á.: Age and lymphocyte/monocyte ratio as prognostic factors for autologous transplantation in the treatment of patients with follicular lymphoma.
J. Int. Med. Res. 52 (2), 1-10, 2024.

doi DEA WoS Scopus

Journal metrics:

Q3 Biochemistry

Q3 Biochemistry (medical)

Q4 Cell Biology

Q3 Medicine (miscellaneous)

22.

Brúgós, B., Simon, Z., Zsigmond Soós, I., Illés, Á.: A hideg agglutinin betegség diagnosztikája és ellátási gyakorlata.
Hematol. Trasnzfuziol. 57 (3), 209-217, 2024.

doi DEA

23.

Gulyás, A., Pinczés, L. I., Mátyus, J., Végh, E., Bedekovics, J., Tóth, J., Barna, S., Hunya, Z., Szabó, I. L., Gazdag, A., Illés, Á., Magyari, F.: Case report: targeted treatment strategies for Erdheim-Chester disease.
Front Oncol. 14, 1-6, (article identifier: 1305518), 2024.

doi DEA WoS Scopus

Journal metrics:

Q2 Cancer Research

Q2 Oncology

24.

Brúgós, B., Simon, Z., Méhes, G., Illés, Á., Pfliegler, G.: Diagnostic challenges in patients with Castleman disease, a single center experience from Hungary.
Pathol. Oncol. Res. 30, 1-10, (article identifier: 1611785), 2024.

doi DEA WoS Scopus

Journal metrics:

Q3 Cancer Research

Q2 Medicine (miscellaneous)

Q2 Oncology

Q2 Pathology and Forensic Medicine

25.

Bicskó, R. R., Illés, Á., Hevessy, Z., Ivády, G., Kerekes, G., Méhes, G., Csépány, T., Gergely, L.: Eculizumab Treatment of Massive Hemolysis Occurring in a Rare Co-Existence of Paroxysmal Nocturnal Hemoglobinuria and Myasthenia Gravis.
Hematol Rep. 16 (2), 255-259, 2024.

doi DEA WoS Scopus

Journal metrics:

Q3 Hematology

Illés Árpád

Publication list